A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health
Part of paid clinical trials in Washington D.C., District of Columbia.
- Sponsor
- International AIDS Vaccine Initiative
- Study ID
- NCT07565090
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Sudan Virus Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 50 Years
- Healthy Volunteers
- Accepted
Interventions
- rVSVΔG-SUDV-GP — BIOLOGICALrVSVΔG-SUDV-GP
- Placebo — OTHERPlacebo
Study Details
A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health.
Key Dates
- First listed
- May 4, 2026
- Start date
- May 8, 2026
- Status verified
- Jun 2026
- Primary completion
- Apr 30, 2027
- Completion
- Apr 30, 2027
Study Design
- Enrollment
- 112 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- PREVENTION
Arms
- Experimental: rVSVΔG-SUDV-GPrVSVΔG-SUDV-GP
- Placebo Comparator: PlaceboPlacebo/Diluent
Primary Outcome Measure
Safety and tolerability of rVSVΔG-SUDV-GP vaccination: solicited reactogenicity [ Time Frame: 14 Days ]
Central Contacts
- Johannes Beeslaar, MD212-328-7459
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| George Washington University | Washington D.C. | District of Columbia | 20037 | Aimee Desrosiers David Diemert, MD (PRINCIPAL_INVESTIGATOR) |
| Johnson County Clin-Trials | Lenexa | Kansas | 66219 | |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | Lindsey Baden, MD (PRINCIPAL_INVESTIGATOR) |